Stockscreener 앱 받기
0.00
100.00%
-9.71
Fibrogen Inc 주식(FGEN)의 최신 뉴스
Published on: 2026-01-09 00:07:25 - ulpravda.ru
Is FibroGen Inc. stock a buy before product launches2025 Trading Recap & AI Based Trade Execution Alerts - ulpravda.ru
Why FibroGen Inc. stock is a must watch in 2025Market Growth Report & Fast Exit and Entry Trade Guides - ulpravda.ru
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum - MarketScreener
FibroGen (FGEN) Faces Option Delistings as of January 8th - GuruFocus
One new option listing and one option delisting on January 8th - TipRanks
FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB By Investing.com - Investing.com Nigeria
FibroGen (FGEN) Transforms into Kyntra Bio with a New Focus - GuruFocus
FibroGen stock rises after announcing rebrand to Kyntra Bio By Investing.com - Investing.com South Africa
FibroGen, Inc. Rebrands to Kyntra Bio, Targeting Oncology and Rare Disease Therapeutics with New Nasdaq Trading Symbol "KYNB" - Quiver Quantitative
FibroGen rebrands to Kyntra Bio - MarketScreener
Cancer and rare disease drug maker Kyntra Bio is born from FibroGen - Stock Titan
Quarterly Earnings: Is FibroGen Inc stock a buy before product launchesJuly 2025 Review & Weekly Momentum Picks - moha.gov.vn
FibroGen shares advance after roxadustat earns orphan drug status - MSN
How FibroGen Inc. stock reacts to inflationary pressuresSwing Trade & Real-Time Buy Zone Alerts - Улправда
Published on: 2025-12-20 23:42:14 - Улправда
Why FibroGen Inc. (1FG0) stock attracts HNW investorsRecession Risk & Reliable Breakout Stock Forecasts - Улправда
FibroGen Q3 2025 Earnings Preview - MSN
Published on: 2025-12-19 15:46:05 - Улправда
Will FibroGen Inc. stock outperform international peers2025 Market Trends & Safe Capital Preservation Plans - Улправда
Published on: 2025-12-18 12:26:14 - Улправда
Is FibroGen (NASDAQ:FGEN) A Risky Investment? - simplywall.st
FDA grants orphan drug designation to FibroGen’s roxadustat for MDS By Investing.com - Investing.com Nigeria
FDA grants orphan drug designation to FibroGen’s roxadustat for MDS - Investing.com India
FibroGen stock rises after roxadustat receives Orphan Drug Designation By Investing.com - Investing.com Nigeria
FibroGen stock rises after roxadustat receives Orphan Drug Designation - Investing.com India
FibroGen (FGEN) Gains FDA Orphan Drug Status for Roxadustat - GuruFocus
Roxadustat granted orphan drug designation for the treatment of myelodysplastic syndromes by the U.S. FDA - marketscreener.com
FibroGen Receives FDA Orphan Drug Designation for Roxadustat in Myelodysplastic Syndromes, Phase 3 Protocol Set for Q4 2025 Submission - Quiver Quantitative
Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration - The Manila Times
Roxadustat Granted Orphan Drug Designation for the - GlobeNewswire
Market Review: Will FibroGen Inc stock keep outperforming rivals2025 Risk Factors & Breakout Confirmation Trade Signals - moha.gov.vn
FibroGen Investor Suit Dismissed Following $28.5 Million Deal - Bloomberg Law News
Can FibroGen Inc. (1FG0) stock deliver strong annual returnsSell Signal & AI Powered Market Entry Strategies - Newser
Will FibroGen Inc. (1FG0) stock outperform global peers2025 Valuation Update & Safe Capital Growth Stock Tips - Newser
FibroGen (FGEN) Stock Analysis Report | Financials & Insights - Benzinga
Is FibroGen Inc. (1FG0) stock overpriced at current multiplesDividend Hike & Weekly Momentum Picks - Newser
How FibroGen Inc. (1FG0) stock reacts to fiscal policiesWeekly Trade Review & Weekly Watchlist for Hot Stocks - Newser
How dovish Fed policy supports FibroGen Inc. (1FG0) stockAnalyst Downgrade & Entry and Exit Point Strategies - Newser
How supply shortages influence FibroGen Inc. (1FG0) stockSell Signal & Weekly Return Optimization Alerts - Newser
Is FibroGen Inc. (1FG0) stock a top hedge fund pick2025 Fundamental Recap & Smart Allocation Stock Tips - Newser
0.80%
4.56%
자본화:
|
볼륨(24시간):